Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Teva- Pharmaceutical Industries Ltd. ADR shares valued at $105,628 were purchased by Shields Matthew on Jun 03 ’25. At $17.02 per share, Shields Matthew acquired 6,206 shares.
Also, Sabag Mark sold 337,915 shares, netting a total of over 6,097,304 in proceeds. Following the sale of shares at $18.04 each, the insider now holds 150,996 shares.
Before that, Sabag Mark had added 337,915 shares to its account. In a trade valued at $6,097,324, the Officer bought Teva- Pharmaceutical Industries Ltd. ADR shares for $18.04 each.
As published in their initiating research note from Truist on May 28, 2025, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] has been a Buy and the price target has been revised to $25. Analysts at JP Morgan upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in mid May. As of July 10, 2024, Argus has increased its “Hold” rating to a “Buy” for TEVA. Earlier on March 08, 2024, JP Morgan upgraded its rating. Their new recommendation was “a Neutral” for TEVA stock which previously was a “an Underweight”.
Analyzing TEVA Stock Performance
During the last five days, there has been a drop of approximately -3.47%. Over the course of the year, Teva- Pharmaceutical Industries Ltd. ADR shares have dropped approximately -20.51%. Shares of the company reached a 52-week high of $22.40 on 01/28/25 and a 52-week low of $12.47 on 04/10/25.
Support And Resistance Levels for Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
According to the 24-hour chart, there is a support level at 17.22, which, if violated, would cause prices to drop to 16.91. In the upper region, resistance lies at 17.74. The next price resistance is at 17.96. RSI (Relative Strength Index) is 57.13 on the 14-day chart, showing neutral technical sentiment.
